A Physician-Driven Solution-The Association for Medical Ethics, The Physician Payment Sunshine Act, and Ethical Challenges in Pain Medicine

Pain Medicine

Volumn 12, Issue 9, 2011, Pages 1361-1375

  Perret, Danielle ^a   Rosen, Charles ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Association for Medical Ethics; Chronic Pain; Conflicts of Interest; Ethics; Industry; Lumbar Disc Replacement; Opioids; Orthopedics; Physician Payment Sunshine Act

Indexed keywords

FENTANYL; OPIATE; OXYCODONE;

ARTICLE; CANCER PAIN; CHRONIC PAIN; CONSTIPATION; DRUG ABUSE; DRUG INDUSTRY; DRUG OVERDOSE; FIBROMYALGIA; HEADACHE; HEALTH CARE POLICY; HUMAN; HYPERALGESIA; LOW BACK PAIN; MEDICAL EDUCATION; MEDICAL ETHICS; MEDICAL PRACTICE; MEDICAL RESEARCH; MEDICAL SOCIETY; ORTHOPEDIC SURGERY; PAIN ASSESSMENT; PHYSICIAN PAYMENT SUNSHINE ACT; PRESCRIPTION; PUBLICATION; RISK ASSESSMENT; SEDATION; SIDE EFFECT;

EID: 80052861919     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2011.01217.x     Document Type: Editorial

References (120)

1. Manchikanti L, Singh A. Therapeutic opioids: A ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 2008;11:S63-88.
2. Crowley-Matoka M, Saha S, Dobscha SK, Burgess DJ. Problems of quality and equity in pain management: Exploring the role of biomedical culture. Pain Med 2009;10:1312-24.
3. Medicare Payment Advisory Commission. Report to the Congress: Paying for Interventional Pain Services in Ambulatory Settings. Washington, DC: MedPAC. December, 2001. Available at:
4. Helm S, Glaser S, Falco F, Henry B. A medical-legal review regarding the standard of care for epidural injections, with particular reference to a closed case. Pain Physician 2010;13:145-50.
5. Manchikanti L, Singh V, Boswell MV. Interventional pain management at crossroads: The perfect storm brewing for a new decade of challenges. Pain Physician 2010;13:E111-40.
6. Freburger JK, Holmes GM, Agans RP, etal. The rising prevalence of chronic low back pain. Arch Intern Med 2009;169:251-8.
7. Manchikanti L, Singh V, Datta S, Cohen SP, Hirsch JA. Comprehensive review of epidemiology, scope, and impact of spinal pain. Pain Physician 2009;12:E35-70.
8. Deshpande A, Furlan A, Mailis-Gagnon A, Atlas S, Turk D. Opioids for chronic low-back pain. Cochrane Database Syst Rev 2007;(3):CD004959.
9. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects. CMAJ 2006;174:1589-94.
10. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Pain 2004;112:372-80.
11. Martell BA, O'Connor PG, Kerns RD, etal. Systematic review: Opioid treatment for chronic back pain: Prevalence, efficacy, and association with addiction. Ann Intern Med 2007;146:116-27.
12. Saper JR, Lake AE 3rd, Hamel RL, etal. Daily scheduled opioids for intractable head pain: Long-term observations of a treatment program. Neurology 2004;62:1687-94.
13. Bogduk N, Fraifeld EM. Proof or consequences: Who shall pay for the evidence in pain medicine? Pain Med 2010;11:1-2.
14. Manchikanti L, Falco FJ, Boswell MV, Hirsch JA. Facts, fallacies, and politics of comparative effectiveness research: Part I. Basic considerations. Pain Physician 2010;13:E23-54.
15. Manchikanti L, Falco FJ, Boswell MV, Hirsch JA. Facts, fallacies, and politics of comparative effectiveness research: Part 2 Implications for interventional pain management. Pain Physician 2010;13:E55-79.
16. Benyamin RM, Datta S, Falco FJ. A perfect storm in interventional pain management: Regulated, but unbalanced. Pain Physician 2010;13:109-16.
17. Manchikanti L, Pampati S, Cash KA. Making sense of the accuracy of diagnostic lumbar facet joint nerve blocks: An assessment of the implications of 50% relief, 80% relief, single block, or controlled diagnostic blocks. Pain Physician 2010;13:133-43.
18. Manchikanti L, Boswell MV, Singh V, etal. Comprehensive evidence-based guidelines for interventional techniques in the management of chronic spinal pain. Pain Physician 2009;12:699-802.
19. Atluri S, Datta S, Falco FJ, Lee M. Systematic review of diagnostic utility and therapeutic effectiveness of thoracic facet joint interventions. Pain Physician 2008;11:611-29.
20. Falco FJ, Erhart S, Wargo BW, etal. Systematic review of diagnostic utility and therapeutic effectiveness of cervical facet joint interventions. Pain Physician 2009;12:323-44.
21. Datta S, Lee M, Falco FJ, Bryce DA, Hayek SM. Systematic assessment of diagnostic accuracy and therapeutic utility of lumbar facet joint interventions. Pain Physician 2009;12:437-60.
22. Manchikanti L, Boswell MV, Singh V, etal. Comprehensive review of neurophysiologic basis and diagnostic interventions in managing chronic spinal pain. Pain Physician 2009;12:E71-120.
23. Schofferman J. Interventional pain medicine: Financial success and ethical practice: An oxymoron? Pain Med 2006;7:457-60.
24. Zientek D. Physician entrepreneurs, self-referral, and conflicts of interest: An overview. HEC Forum 2003;15:111-33.
25. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA 2003;290:252-5.
26. Geisler FH, Blumenthal SL, Guyer RD, etal. Neurological complications of lumbar artificial disc replacement and comparison of clinical results with those related to lumbar arthrodesis in the literature: Results of a multicenter, prospective, randomized investigational device exemption study of Charite intervertebral disc. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004. J Neurosurg Spine 2004;1:143-54.
27. Button G, Gupta M, Barrett C, Cammack P, Benson D. Three- to six-year follow-up of stand-alone BAK cages implanted by a single surgeon. Spine J 2005;5:155-60.
28. Centers for Medicare and Medicaid Services. Decision Memo for Lumbar Artificial Disc Replacement. Baltimore, MD: Centers for Medicare and Medicaid Services; May 16, 2006.
29. Center for Devices and Radiological Health. Charité artificial disc-P040006. Silver Spring, MD: US Food and Drug Administration; October 26, 2004.
30. Brox JI, Reikeras O, Nygaard O, etal. Lumbar instrumented fusion compared with cognitive intervention and exercises in patients with chronic back pain after previous surgery for disc herniation: A prospective randomized controlled study. Pain 2006;122:145-55.
31. Brox JI, Sorensen R, Friis A, etal. Randomized clinical trial of lumbar instrumented fusion and cognitive intervention and exercises in patients with chronic low back pain and disc degeneration. Spine 2003;28:1913-21.
32. Fairbank J, Frost H, Wilson-MacDonald J, etal. Randomised controlled trial to compare surgical stabilisation of the lumbar spine with an intensive rehabilitation programme for patients with chronic low back pain: The MRC spine stabilisation trial. BMJ 2005;330:1233.
33. Mirza SK, Deyo RA. Systematic review of randomized trials comparing lumbar fusion surgery to nonoperative care for treatment of chronic back pain. Spine 2007;32:816-23.
34. Giordano J. Techniques, technology and tekne: The ethical use of guidelines in the practice of interventional pain management. Pain Physician 2007;10:1-5.
35. Cilliers P. Complexity and Postmodernism. New York: Routledge; 1998.
36. Sackett D. Evidence-Based Medicine. How to Practice and Teach EBM, 2nd edition. Toronto, ON: Churchill-Livingston; 2000.
37. Weiner BK, Levi BH. The profit motive and spine surgery. Spine 2004;29:2588-91.
38. Macpherson C. Undertreating pain violates ethical principles. J Med Ethics 2009;35:603-6.
39. Manchikanti L, Damron KS, McManus CD, Barnhill RC. Patterns of illicit drug use and opioid abuse in patients with chronic pain at initial evaluation: A prospective, observational study. Pain Physician 2004;7:431-7.
40. Manchikanti L, Damron KS, Pampati V, McManus CD. Prospective evaluation of patients with increasing opiate needs: Prescription opiate abuse and illicit drug use. Pain Physician 2004;7:339-44.
41. Van Zee A. The promotion and marketing of oxycontin: Commercial triumph, public health tragedy. Am J Public Health 2009;99:221-7.
42. Basler MH. Bad medicine: Pain. Ignorance, opioids, and bliss. BMJ 2010;340:c458.
43. Weisner CM, Campbell CI, Ray GT, etal. Trends in prescribed opioid therapy for non-cancer pain for individuals with prior substance use disorders. Pain 2009;145:287-93.
44. Chou R, Fanciullo GJ, Fine PG, etal. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30.
45. Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. J Pain 2006;7:225-35.
46. Burckhardt CS, Goldenberg D, Crofford L, etal. Guideline for the Management of Fibromyalgia Syndrome Pain in Adults and Children. Glenview, IL: American Pain Society; 2005.
47. Ballantyne JC, Fleisher LA. Ethical issues in opioid prescribing for chronic pain. Pain 2010;148:365-7.
48. Dubois MY. The birth of an ethics charter for pain medicine. Pain Med 2005;6:201-2.
49. Joranson DEGA. State intractable pain policy: Current status. In: (APS) Aps, ed. APS Bulletin; 1997:7-9.
50. Dahl JLGD. Joint commission pain standards: A progress report. In: (APS) Aps, ed. APS Bulletin; 2002:1-8.
51. Vila H Jr, Smith RA, Augustyniak MJ, etal. The efficacy and safety of pain management before and after implementation of hospital-wide pain management standards: Is patient safety compromised by treatment based solely on numerical pain ratings? Anesth Analg 2005;101:474-80. Table of contents.
52. Passik SD, Messina J, Golsorkhi A, Xie F. Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain. J Pain Symptom Manage 2011;41:116-25.
53. Engelbert RH, van Bergen M, Henneken T, Helders PJ, Takken T. Exercise tolerance in children and adolescents with musculoskeletal pain in joint hypermobility and joint hypomobility syndrome. Pediatrics 2006;118:e690-6.
54. Sherbourne CD, Asch SM, Shugarman LR, etal. Early identification of co-occurring pain, depression and anxiety. J Gen Intern Med 2009;24:620-5.
55. Ilgen MA, Zivin K, McCammon RJ, Valenstein M. Pain and suicidal thoughts, plans and attempts in the United States. Gen Hosp Psychiatry 2008;30:521-7.
56. Collen M. The case for pain insomnia depression syndrome (PIDS): A symptom cluster in chronic nonmalignant pain. J Pain Palliat Care Pharmacother 2008;22:221-5.
57. de Jong JR, Vangronsveld K, Peters ML, etal. Reduction of pain-related fear and disability in post-traumatic neck pain: A replicated single-case experimental study of exposure in vivo. J Pain 2008;9:1123-34.
58. Heim N, Snijder MB, Deeg DJ, Seidell JC, Visser M. Obesity in older adults is associated with an increased prevalence and incidence of pain. Obesity 2008;16:2510-7.
59. Wild D. Studies revive debate on opioid-induced hyperalgesia. Pain Medicine News 2010;7:1, 47.
60. Ustun F, Durmus-Altun G, Altaner S, etal. Evaluation of morphine effect on tumour angiogenesis in mouse breast tumour model, EATC. Med Oncol 2010 [Epub ahead of print].
61. Kendall SE, Sjogren P, Pimenta CA, Hojsted J, Kurita GP. The cognitive effects of opioids in chronic non-cancer pain. Pain 2010;150:225-30.
62. Fine PG, Messina J, Xie F, Rathmell J. Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: An 18-month study. J Pain Symptom Manage 2010;40:747-60.
63. Portenoy RK, Farrar JT, Backonja MM, etal. Long-term use of controlled-release oxycodone for noncancer pain: Results of a 3-year registry study. Clin J Pain 2007;23:287-99.
64. Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: A review of the evidence. Clin J Pain 2008;24:469-78.
65. Dillie KS, Fleming MF, Mundt MP, French MT. Quality of life associated with daily opioid therapy in a primary care chronic pain sample. J Am Board Fam Med 2008;21:108-17.
66. Eriksen J, Sjogren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: An epidemiological study. Pain 2006;125:172-9.
67. Wallace AS, Freburger JK, Darter JD, Jackman AM, Carey TS. Comfortably numb? Exploring satisfaction with chronic back pain visits. Spine J 2009;9:721-8.
68. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2007 National Survey on Drug Use and Health: National Findings (NSDUH Series H-34, DHHS Publication No. SMA 08-4343). Rockville, MD, 2008.
69. Kuehn BM. Opioid prescriptions soar: Increase in legitimate use as well as abuse. JAMA 2007;297:249-51.
70. Kuehn BM. Efforts aim to curb opioid deaths, injuries. JAMA 2009;301:1213-5.
71. Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med 2006;31:506-11.
72. The National Center on Addiction and Substance Abuse at Columbia University. Under the Counter: The Diversion and Abuse of Controlled Prescription Drugs in the U.S. New York: Author; 2005.
73. Chou R, Ballantyne JC, Fanciullo GJ, Fine PG, Miaskowski C. Research gaps on use of opioids for chronic noncancer pain: Findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009;10:147-59.
74. Society TBP. Recommendations for the Appropriate Use of Opioids for Persistent Non-Cancer Pain. London: The British Pain Society; 2005.
75. Graziotti PGR. The use of oral opioids in patients with chronic nonmalignant pain: Management strategies. Med J Aust 1997;167:30-4.
76. Kalso E, Allan L, Dellemijn PL, etal. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 2003;7:381-6.
77. Jovey RD, Ennis J, Gardner-Nix J, etal. Use of opioid analgesics for the treatment of chronic noncancer pain: A consensus statement and guidelines from the Canadian Pain Society, 2002. Pain Res Manag 2003;8:3A-28A.
78. Trescot AM, Boswell MV, Atluri SL, etal. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006;9:1-39.
79. Fine PG, Narayana A, Passik SD. Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: Appropriate patient selection and management. Pain Med 2010;11:1024-36.
80. Portenoy RK, Hagen NA. Breakthrough pain: Definition, prevalence and characteristics. Pain 1990;41:273-81.
81. Mercadante S, Radbruch L, Caraceni A, etal. Episodic (breakthrough) pain: Consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002;94:832-9.
82. Markman JD. Not so fast: The reformulation of fentanyl and breakthrough chronic non-cancer pain. Pain 2008;136:227-9.
83. Gilron I, Orr E, Tu D, etal. A placebo-controlled randomized clinical trial of perioperative administration of gabapentin, rofecoxib and their combination for spontaneous and movement-evoked pain after abdominal hysterectomy. Pain 2005;113:191-200.
84. Manchikanti L, Singh V, Caraway DL, Benyamin RM. Breakthrough pain in chronic non-cancer pain: Fact, fiction, or abuse. Pain Physician 2011;14:E103-17.
85. Nicholson B. Benefits of extended-release opioid analgesic formulations in the treatment of chronic pain. Pain Pract 2009;9:71-81.
86. Devulder J, Jacobs A, Richarz U, Wiggett H. Impact of opioid rescue medication for breakthrough pain on the efficacy and tolerability of long-acting opioids in patients with chronic non-malignant pain. Br J Anaesth 2009;103:576-85.
87. Bennett DS, Simon S, Brennan M, Shoemaker SA. Prevalence and characteristics of breakthrough pain in patients receiving opioids for chronic back pain in pain specialty clinics. J Opioid Manag 2007;3:101-6.
88. Portenoy RK, Bennett DS, Rauck R, etal. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain 2006;7:583-91.
89. Simon S, Bennett DS, Rauck R, Taylor D, Shoemaker S. Breakthrough pain in opioid-treated patients with neuropathic pain. J Opioid Manag 2006;2:347-52.
90. McCarberg BH. The treatment of breakthrough pain. Pain Med 2007;8(suppl 1):S8-13.
91. Portenoy RK, Messina J, Xie F, Peppin J. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: A randomized, placebo-controlled study. Curr Med Res Opin 2007;23:223-33.
92. Simpson DM, Messina J, Xie F, Hale M. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: A multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2007;29:588-601.
93. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007;5:327-34.
94. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease admitted to a hospice. Palliat Med 2001;15:243-6.
95. Bohnert AS, Valenstein M, Bair MJ, etal. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011;305:1315-21.
96. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug Alcohol Depend 2006;81:103-7.
97. Cephalon I. NDA 21-947. FENTORA (fentanyl buccal tablet) CII. Cephalon, Inc. In: Committee. ACBDUSFaDAJMAaLSDACaDSaRMA, ed. 2008.
98. Wright CT, Schnoll S, Bernstein D. Risk evaluation and mitigation strategies for drugs with abuse liability: Public interest, special interest, conflicts of interest, and the industry perspective. Ann N Y Acad Sci 2008;1141:284-303.
99. E-News A. FDA advisory panel rejects opioid REMS proposal; 2010.
100. Edlund MJ, Steffick D, Hudson T, Harris KM, Sullivan M. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain 2007;129:355-62.
101. Ives TJ, Chelminski PR, Hammett-Stabler CA, etal. Predictors of opioid misuse in patients with chronic pain: A prospective cohort study. BMC Health Serv Res 2006;6:46.
102. Schofferman J, Banja J. Conflicts of interest in pain medicine: Practice patterns and relationships with industry. Pain 2008;139:494-7.
103. Hooked BH. Ethics, the Medical Profession, and the Pharmaceutical Industry. Lantham, MD: Rowman & Littlefield; 2007.
104. Fauber J. Medical device maker paid US surgeon $19 million. Milwaukee Journal Sentinel; 2009; Jan 16.
105. Garber K. Committee questions a top psychiatrist. U.S. News and World Report. 2008.
106. RxPromoROI. The RAPP study: Executive summary (n.d.).
107. Steinbrook R. Financial support of continuing medical education. JAMA 2008;299:1060-2.
108. Angell M. Big pharm, bad medicine. Boston Review. 2010.
109. Harris GCB. Researchers fail to reveal full drug pay. The New York Times; 2008.
110. Willman D. Panel challenges NIH handling of rules violations. LA Times; 2006.
111. Campbell EG, Weissman JS, Vogeli C, etal. Financial relationships between institutional review board members and industry. N Engl J Med 2006;355:2321-9.
112. Shah RV, Albert TJ, Bruegel-Sanchez V, etal. Industry support and correlation to study outcome for papers published in Spine. Spine 2005;30:1099-104. Discussion 105.
113. Barden J, Derry S, McQuay HJ, Moore RA. Bias from industry trial funding? A framework, a suggested approach, and a negative result. Pain 2006;121:207-18.
114. DeAngelis CD, Fontanarosa PB. Impugning the integrity of medical science: The adverse effects of industry influence. JAMA 2008;299:1833-5.
115. Dubois MY. American academy of pain medicine ethics council statement on conflicts of interest: Interaction between physicians and industry in pain medicine. Pain Med 2010;11:257-62.
116. Code of Medial Ethics of the American Medical Association-Committee on Ethical and Judicial Affairs. Opinion E-8061: Gifts to Physicians from Industry. Chicago, IL: AMA; 2008.
117. Thompson DF. Understanding financial conflicts of interest. N Engl J Med 1993;329:573-6.
118. 110-578 SH. Surgeons for sale: Conflicts and consultant payment in the medical device industry. In: Aging HbtSCo, ed. Washington, DC: U.S. Government Printing Office; 2008.
119. 3590 H. Patient Protection and Affordability Care Act. Washington, DC: Library of Congress; 2010:1543-63.
120. Whalen J, Mundy A. FDA scientist attacks Avandia study. Wall Street Journal; 2010; Jun 11.